BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 3944268)

  • 21. Gynecological malignancies.
    Schaebler DL; Schilder RJ; Young RC
    Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction and removal of cisplatin-DNA adducts in human cells in vivo and in vitro as measured by immunochemical techniques.
    Fichtinger-Schepman AM; Dijt FJ; Bedford P; van Oosterom AT; Hill BT; Berends F
    IARC Sci Publ; 1988; (89):321-8. PubMed ID: 3198216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trans-diammineplatinum(II): what makes it different from cis-DDP? Coordination chemistry of a neglected relative of cisplatin and its interaction with nucleic acids.
    Lippert B
    Met Ions Biol Syst; 1996; 33():105-41. PubMed ID: 8742842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9048 and Children's Cancer Group 8891.
    Rogers PC; Olson TA; Cullen JW; Billmire DF; Marina N; Rescorla F; Davis MM; London WB; Lauer SJ; Giller RH; Cushing B; ;
    J Clin Oncol; 2004 Sep; 22(17):3563-9. PubMed ID: 15337806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
    Darcy KM; Tian C; Reed E
    Cancer Res; 2007 May; 67(9):4474-81. PubMed ID: 17483363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cisplatin based chemotherapy in testicular cancer patients: long term platinum excretion and clinical effects.
    Hohnloser JH; Schierl R; Hasford B; Emmerich B
    Eur J Med Res; 1996 Sep; 1(11):509-14. PubMed ID: 9438151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The measurement of cisplatin-DNA adduct levels in testicular cancer patients.
    Reed E; Ozols RF; Tarone R; Yuspa SH; Poirier MC
    Carcinogenesis; 1988 Oct; 9(10):1909-11. PubMed ID: 2458857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.
    Cushing B; Giller R; Cullen JW; Marina NM; Lauer SJ; Olson TA; Rogers PC; Colombani P; Rescorla F; Billmire DF; Vinocur CD; Hawkins EP; Davis MM; Perlman EJ; London WB; Castleberry RP; ;
    J Clin Oncol; 2004 Jul; 22(13):2691-700. PubMed ID: 15226336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Axial ligands and alicyclic ring size modulate the activity and biochemical pharmacology of ammine/cycloalkylamine-platinum(IV) complexes in tumor cells resistant to cis-diamminedichloroplatinum(II) or trans-1R,2R-1S,2S-diaminocyclohexanetetrachloroplatinum(IV).
    Yoshida M; Khokhar AR; Siddik ZH
    Cancer Res; 1994 Sep; 54(17):4691-7. PubMed ID: 8062266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
    Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cisplatin-DNA adducts and protein-bound platinum in blood of testicular cancer patients.
    Boffetta P; Fichtinger-Schepman AM; Weiderpass E; van Dijk-Knijnenburg HC; Stoter G; van Oosterom AT; Keizer HJ; Fosså SD; Kaldor J; Roy P
    Anticancer Drugs; 1998 Feb; 9(2):125-9. PubMed ID: 9510497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. cis-Diamminedichloroplatinum(II) alone and in combination in the treatment of testicular and other malignancies.
    Sarna G; Skinner DG; Smith RB; Zighelboim J; Goodnight JE; Feig S
    Cancer Treat Rep; 1980; 64(10-11):1077-82. PubMed ID: 7193086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Capillary electrophoretic separation and laser-induced fluorescence detection of the major DNA adducts of cisplatin and carboplatin.
    Sharma M; Jain R; Ionescu E; Slocum HK
    Anal Biochem; 1995 Jul; 228(2):307-11. PubMed ID: 8572311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies.
    Reed E; Parker RJ; Gill I; Bicher A; Dabholkar M; Vionnet JA; Bostick-Bruton F; Tarone R; Muggia FM
    Cancer Res; 1993 Aug; 53(16):3694-9. PubMed ID: 8339278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
    Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of the DNA damage recognized by an antiserum elicited against cis-diamminedichloroplatinum (II)-modified DNA.
    Reed E; Gupta-Burt S; Litterst CL; Poirier MC
    Carcinogenesis; 1990 Dec; 11(12):2117-21. PubMed ID: 1979937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.
    Hoebers FJ; Pluim D; Hart AA; Verheij M; Balm AJ; Fons G; Rasch CR; Schellens JH; Stalpers LJ; Bartelink H; Begg AC
    Cancer Chemother Pharmacol; 2008 May; 61(6):1075-81. PubMed ID: 17639394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [First therapeutic experience with cis-platinum(II)diamindichloride (NSC 119875) in metastasizing ovarian and testicular carcinoma].
    Cavalli F; Sonntag RW; Ryssel HJ; Tschopp L; Brunner KW
    Schweiz Med Wochenschr; 1976 May; 106(22):754-7. PubMed ID: 996494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.